1. Management of VEGF-Targeted Therapy-Induced Hypertension.
- Author
-
Caletti S, Paini A, Coschignano MA, De Ciuceis C, Nardin M, Zulli R, Muiesan ML, Salvetti M, and Rizzoni D
- Subjects
- Humans, Neoplasms drug therapy, Antineoplastic Agents, Immunological adverse effects, Hypertension chemically induced, Hypertension drug therapy, Medication Therapy Management, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Purpose of Review: From a physiological point of view, VEGFs (vascular endothelial growth factors) and their receptors (VEGFR) play a critical role in vascular development angiogenesis, endothelial function, and vascular tone. On the pathological side, VEGF-VEGFR signaling may induce dysregulated angiogenesis, which contributes to the growth and to the spread of tumors, being essential for neoplastic proliferation and invasion., Recent Findings: Pharmacological inhibition of VEGF-VEGFR is now a cornerstone in the treatment of many malignancies; however, treatment with VEGF inhibitors is commonly associated with an increase in blood pressure values. This side effect is strictly connected with the mechanism of action of these medications and might represent an index of therapy efficacy. The optimal management of this form of hypertension is, at present, not clear. Calcium channel blockers and renin-angiotensin system inhibitors probably represent the most appropriate classes of hypertensive dugs for the treatment of this condition; however, no conclusive data are presently available.
- Published
- 2018
- Full Text
- View/download PDF